Recursion Pharmaceuticals Inc - Class A

Research Recursion Pharmaceuticals Inc - Class A (RXRX) on Bullrun: market cap USD 1.96B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRXRX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.96B
• Financial periodFY2025
• RevenueUSD 74.68M
• Revenue growth26.9%
• Net income-USD 644.76M
• Free cash flow-USD 378.28M
• Gross margin5.0%

Valuation Snapshot

latest market cap is USD 1.96B.

About Recursion Pharmaceuticals Inc - Class A

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors;

Frequently asked questions

What is Recursion Pharmaceuticals Inc - Class A's market cap?

Recursion Pharmaceuticals Inc - Class A's market capitalization is USD 1.96B.

What does Recursion Pharmaceuticals Inc - Class A do?

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United...